MaxCyte
Vertex Pharmaceuticals secures exa-cel SPLMaxCyte
Strategic investments to support partners & future growthMaxCyte
Robust Cell Therapy performance lifts FY22 guidanceMaxCyte
Sustained FY21 growth with significantly more potentialMaxCyte
Opening the next chapterMaxCyte
Nkarta signs SPL to accelerate its NK cell therapiesMaxCyte
Catching an unbroken waveMaxCyte
Better visibility brings future into focusMaxCyte
US institutional private placing raises £40mMaxCyte
In the vanguard of next-generation cell and gene therapies